Let's Talk... lung cancer at ESMO 2021

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site

Sep 22 / Springer Healthcare

Let's Talk... lung cancer at ESMO 2021

Oncology Lung Cancer ESMO-2021

Description

In this episode, Antonio Passaro puts in context the findings of the BEVERLY, WJOG 9717L and ETOP BOOSTER trials of combined treatment with bevacizumab and an EGFR–tyrosine kinase inhibitor in EGFR-positive advanced non-small-cell lung cancer.

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.